|
A phase 2 trial of ALIMTA (LY231514, pemetrexed) plus oxaliplatin administered every 21 days for first-line treatment of patients with advanced colorectal cancer. Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about A phase 2 trial of ALIMTA (LY231514, pemetrexed) plus oxaliplatin administered every 21 days for first-line treatment of patients with advanced colorectal cancer. conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. A phase 2 trial of ALIMTA (LY231514, pemetrexed) plus oxaliplatin administered every 21 days for first-line treatment of patients with advanced colorectal cancer. Clinical research trials and A phase 2 trial of ALIMTA (LY231514, pemetrexed) plus oxaliplatin administered every 21 days for first-line treatment of patients with advanced colorectal cancer. health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including A phase 2 trial of ALIMTA (LY231514, pemetrexed) plus oxaliplatin administered every 21 days for first-line treatment of patients with advanced colorectal cancer.. A phase 2 trial of ALIMTA (LY231514, pemetrexed) plus oxaliplatin administered every 21 days for first-line treatment of patients with advanced colorectal cancer. Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a A phase 2 trial of ALIMTA (LY231514, pemetrexed) plus oxaliplatin administered every 21 days for first-line treatment of patients with advanced colorectal cancer. clinical trial. Human subjects often get the best healthcare possible for their A phase 2 trial of ALIMTA (LY231514, pemetrexed) plus oxaliplatin administered every 21 days for first-line treatment of patients with advanced colorectal cancer. condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A phase 2 trial of ALIMTA (LY231514, pemetrexed) plus oxaliplatin administered every 21 days for first-line treatment of patients with advanced colorectal cancer. A phase 2 trial of ALIMTA (LY231514, pemetrexed) plus oxaliplatin administered every 21 days for first-line treatment of patients with advanced colorectal cancer.
A phase 2 trial of ALIMTA (LY231514, pemetrexed) plus oxaliplatin administered every 21 days for first-line treatment of patients with advanced colorectal cancer.
For Condition: Colorectal Cancer
Status: No longer recruiting
Sponsor(s): Eli Lilly and Company ,
Synopsis: The purpose of this study is to assess the antitumor activity of ALIMTA plus Oxaliplatin combination therapy in patients with previously untreated advanced colorectal cancer
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Diagnosis of primary cancer of the colon or rectum - Must have measurable disease - Must be able to comply with study procedure Exclusion Criteria: - Prior chemotherapy for advanced disease - Pregnancy or lactation - Candidates for surgical resection of one or more metastatic foci - Second primary cancer - Inability to take folic acid or vitamin B12
Total Enrollment:
Location and Contact Information:
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Bellevue, Washington,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Asheville, North Carolina,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Latham, New York,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Portland, Oregon,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
St. George, Utah,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Hendersonville, North Carolina,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Seattle, Washington,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Ogden, Utah,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Winston Salem, North Carolina,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Reading, Pennsylvania,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Kalamazoo, Michigan,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Charleston, South Carolina,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Bend, Oregon,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Pittsburgh, Pennsylvania,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Goldsboro, North Carolina,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Huntsville, Alabama,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Pittsfield, Massachusetts,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Columbus, Ohio,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Philadelphia, Pennsylvania,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Provo, Utah,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Spokane, Washington,
United States
"For information on a site near you, call our call center at 1-877-CTLILLY (1-877-285-4559)"
Ivins, Utah,
United States
Additional Information:
Study ID Numbers: 5142;
Study Start Date:
Record last reviewed: June 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00034619
Other Colorectal Cancer Studies:
1. A Phase I Study To Test The Safety Of DAVANAT With and Without 5-Fluorouracil In Patients With Solid Tumors
2. Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer
3. CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer
4. Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors
5. SU-011,248 in Patients with Metastatic Colorectal Cancer who Previously Failed Treatment with Irinotecan-, Oxaliplatin-, and Fluoropyrimidine, with and without Bevacizumab
Related Studies:
Other Colorectal Cancer Clinical Trials
Other Massachusetts Clinical Trials
Other Pittsfield Clinical Trials
A phase 2 trial of ALIMTA (LY231514, pemetrexed) plus oxaliplatin administered every 21 days for first-line treatment of patients with advanced colorectal cancer.
|
|
|
|
|
|
|
|